AllSight
Companies · BLFS · Electromedical & Electrotherapeutic Apparatus · Company update · Aug 6, 2026

Revenue edged past consensus as underlying profitability improved, but margins slipped

BIOLIFE SOLUTIONS INC (BLFS) — what happened, in plain English, and what it means versus what the market expected.
MetricQ2 2026Q2 2025Market expectation / reference
Revenue$28.5M$23.4M~$27.8M consensus
GAAP diluted EPS$0.91$(0.32)~$0.03 consensus
Adjusted net income$4.2M$0.6M—
Adjusted EBITDA$7.4M$5.6M26% margin vs. 24%
GAAP gross margin64%65%—
Adjusted gross margin65%66%—
Read the original 8-K on SEC EDGAR ↗
More from BIOLIFE SOLUTIONS INC (BLFS)
Sep 9, 2026BioLife Solutions clears antitrust hurdle as Repligen deal heads to October voteAll BLFS filings, decoded →
Related companies in Electromedical & Electrotherapeutic Apparatus
ITGRLIVNCBLLMDTAXGNTMDX
Latest across the market
ACNAccenture earnings beat as Q4 revenue clears guidance, but FY27 growth stays measuredROPRoper Technologies adds NTT DATA CEO to board, but brings no operating changeIIPRIIPR loan increase funds Alewife buildout, but locks in 14% debtGLUEMonte Rosa GFORCE-1 results clear safety bar, but ASCVD Phase 2 moves to 2027SMASmartStop dividend holds at $1.60 annualized as October payout repeats patternHBNCHorizon Bancorp schedules Q3 earnings, offering no fresh business readBrowse all companies, decoded →
Open live on AllSight — the whole market, decoded →
AllSight turns SEC filings into plain-English, neutral reads and objective market context. We explain what happened and how it lands versus expectations — we do not give investment advice or predict prices. Decoded straight from the filing; check it against the source.
Analysis by AllSight · Editorial standards & method · Contact